FDA Flags Potential Guillain-Barre Risk with RSV Vaccine Candidates
February 28, 2023
(MedPage) – Ahead of a 2-day meeting with FDA’s vaccine advisors, reviewers at the agency highlighted a rare but potential risk for Guillain-Barré syndrome with two vaccine candidates for respiratory syncytial virus (RSV). On Tuesday and Wednesday, the Vaccines and Related Biological Products Advisory Committee (VRBPAC)opens in a new tab or window will recommend whether the risk-benefit profile with Pfizer and GSK’s vaccine candidates support approval for reducing RSV-related lower respiratory tract infections in adults 60 and up. (Read More)